title: Short-course immunosuppression using FK506 for rat tracheal allografts.
abstract: BACKGROUND
  A minimizing immunosuppression after a tracheal allotransplantation is desirable.
  
  
  METHODS
  We examined the usefulness of a short-course of immunosuppression after tracheal allotransplantation in rat. Each transplant consisting of a 5-ring segment was heterotopically implanted into the omentum. Four animals underwent a syngeneic transplantation and thus served as controls (Group A). Thirty animals underwent an allogeneic transplantation and were randomly classified into 4 groups as follows: No immunosuppression (Group B, n=6), treatment with 0.5 mg/kg of Tacrolims (FK506) (Group C, n=8), 1.0 mg/kg of FK506 (Group D, n=8), and 1.5 mg/kg of FK506 (Group E, n=8). Different doses of FK506 were administered intramuscularly for only three consecutive days after heterotopic tracheal allotransplantation. The serum levels of FK506 were then investigated 3, 7, 14, 21, and 28 days after transplantation in groups C, D, and E. All rats were killed 28 days after transplantation and then the implanted tracheae were harvested, and evaluated histologically.
  
  
  RESULTS
  All animals survived for the protocol period. The graft morphology of Group E was significantly better than that of groups B, C, and D regarding both macro- and microscopy, and also showed the same findings as that of Group A, except for low-grade mononuclear cell infiltration. Only in Group E, the FK506 blood level was maintained at over 0.5 ng/ml, which is the lowest detectable limit in this assay, until 21 days after transplantation.
  
  
  CONCLUSIONS
  We thus conclude that 1.5 mg/kg of FK506 which was administered for only three consecutive days after surgery may be used to maintain the morphology of tracheal allografts in rats for 28 days after transplantation.
authors.affiliation: Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Hashimoto
authors.forename: R
authors.initials: R
authors.lastname: Nakanishi
authors.forename: H
authors.initials: H
authors.lastname: Muranaka
authors.forename: M
authors.initials: M
authors.lastname: Umesue
authors.forename: R
authors.initials: R
authors.lastname: Eifuku
authors.forename: K
authors.initials: K
authors.lastname: Yasumoto
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D006084:Graft Rejection / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D007108:Immune Tolerance / Q000187:drug effects* / Q000276:immunology; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000097:blood; D007273:Injections, Intramuscular; D009852:Omentum / Q000166:cytology / Q000601:surgery*; D011897:Random Allocation; D051381:Rats; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D016559:Tacrolimus / Q000008:administration & dosage* / Q000097:blood; D016378:Tissue Transplantation; D014132:Trachea / Q000166:cytology / Q000637:transplantation*; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus